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Abstract  29 
Imbalance of neuronal proteostasis associated with misfolding and aggregation of Tau protein is a 30 
common neurodegenerative feature in Alzheimer’s disease (AD) and other Tauopathies. Consistent 31 
with suggestions that lifetime stress may be an important AD precipitating factor, we previously 32 
reported that environmental stress and high glucocorticoid (GC) levels induce accumulation of 33 
aggregated Tau; however, the molecular mechanisms for such process remain unclear. Herein, we 34 
monitor a novel interplay between RNA-binding proteins (RBPs) and autophagic machinery in the 35 
underlying mechanisms through which chronic stress and high GC levels impact on Tau proteostasis 36 
precipitating Tau aggregation. Using molecular, pharmacological and behavioral analysis, we 37 
demonstrate that chronic stress and high GC trigger a mTOR-dependent inhibition of autophagy, 38 
leading to accumulation of Tau aggregates and cell death in P301L-Tau expressing mice and cells. 39 
In parallel, we found that environmental stress and GC disturb cellular homeostasis and trigger the 40 
insoluble accumulation of different RBPs, such as PABP, G3BP1, TIA-1, and FUS, shown to form 41 
Stress granules(SGs) and Tau aggregation. Interestingly, an mTOR-driven pharmacological 42 
stimulation of autophagy attenuates the GC-driven accumulation of Tau and SG-related proteins as 43 
well as the related cell death, suggesting a critical interface between autophagy and the response of 44 
the SG-related protein in the neurodegenerative potential of chronic stress and GC. These studies 45 
provide novel insights into the RNA-protein intracellular signaling regulating the precipitating role of 46 
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Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder with a complex 53 
pathophysiology and still undefined initiators. Several risk factors have been associated with AD 54 
pathology, with recent evidence supporting a detrimental role of lifetime stress 1–3. Clinical studies 55 
relate distress, high cortisol levels and dysfunction of hypothalamus-pituitary-adrenal (HPA) axis with 56 
poor memory scores and earlier disease onset in AD patients highlighting the potential implication of 57 
chronic stress and glucocorticoids (GC) in the pathogenesis and/or progression of the disorder 4–6. In 58 
line with the above clinical evidence, experimental studies have shown that chronic stress and 59 
exposure to high GC levels trigger Tau hyperphosphorylation and malfunction leading to its 60 
accumulation, formation of neurotoxic Tau aggregates and AD pathology 1,7,8. Despite our little 61 
knowledge about the molecular mechanisms that underpin stress-driven pathology, experimental 62 
evidence suggests that stress/GC reduces Tau turnover 9, suggesting that stress/GC impact on the 63 
chaperones and proteases that regulate Tau levels 8.  64 
Impaired proteostasis is thought to lead to the accumulation of misfolded and aggregated proteins, 65 
causing a corresponding increase in neuronal vulnerability and neurodegeneration. One sign of 66 
impaired proteostasis is the massive accumulation of autophagic vacuoles and proteins in the 67 
autophagic-lysosomal pathway which occurs in brains of AD cases 10,11. Divided in different steps, 68 
e.g. initiation, elongation and maturation, the (macro)autophagy process critically involves several 69 
evolutionarily-conserved molecules such as the microtubule-associated protein light chain 3 (LC3), 70 
autophagy receptor p62 and (mammalian target of rapamycin) mTOR 12; the latter has been 71 
suggested as therapeutic target against pathological aggregation of Tau and related AD neurotoxicity 72 
13,14. Moreover, inhibition of autophagic-lysosome pathway is also shown to impair the degradation 73 
and dynamics of stress granules (SGs) 15. SGs are cytoplasmic complexes containing mRNAs and 74 
different RNA-binding proteins (RBPs) such as  the SG-associated T cell intracellular antigen 1 (TIA1), 75 
poly(A)-binding protein (PABP), Fused in Sarcoma protein (FUS) and the stress granule assembly 76 
factor, Ras-GTPase-activating protein binding protein 1 (G3BP1) 16. Several SG-associated RBPs 77 
have been associated with neurodegenerative diseases with a close link being recently identified 78 
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between the SGs core-nucleating protein TIA-1 and Tau. Specifically, TIA-1 is shown to bind to Tau 79 
contributing to its aggregation and Tau-related neurodegeneration and toxicity found in AD and other 80 
Tauopathies 17–19. Based on the above, we hereby monitor the role and potential interplay between 81 
autophagy, SG-related proteins and Tau aggregation in stress-driven brain pathology. 82 
 83 
Methods and Materials  84 
Animals and stress protocol  85 
6-8 month old P301L-Tau transgenic mice, expressing mutated (P301L) human Tau under the 86 
CAMKII promoter (N= 7-9 per group) were used in this were used in this study20. All experiments were 87 
conducted in accordance with the Portuguese national authority for animal experimentation, Direcção 88 
Geral de Veterinária (ID: DGV9457). Animals were kept and handled in accordance with the 89 
guidelines for the care and handling of laboratory animals in the Directive 2010/63/EU of the European 90 
Parliament and Council. Mice were housed in groups of 4-5 per cage under standard environmental 91 
conditions (lights on from 8 a.m. [ZT0] to 8 p.m. [ZT12]; room temperature 22ºC; relative humidity of 92 
55%, ad libitum access to food and water). Animals were subjected to chronic unpredictable stress 93 
protocol over a period of four weeks before the behavioral testing. Experiments were replicated 3 94 
times (7-9 mice per group for each experimental replicate). The stress protocol consists of different 95 
stressors such as overcrowding, rocking platform, restrain, hair dryer (one stressor per day) that were 96 
chosen in a random order to prevent habituation. Stress efficacy was monitored by measurements of 97 
daytime serum corticosterone levels (monitored by a radioimmunoassay kit from ICN, Costa Mesa, 98 
CA) and body weight. All stressed animals showed significant elevations in daytime serum 99 
corticosterone levels (p<0.05) and net loss of body weight (p<0.05) reflecting the stress efficacy (see 100 
Figure 1). 101 
  102 
 103 
Behavior Testing 104 
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Open Field (OF) test was conducted in an arena (43.2 cm43.2 cm) with transparent acrylic walls and 105 
white floor (Med Associates Inc., St. Albans, VT, USA). Mice were placed in the center of the arena 106 
and their movement was automatically monitored over a period of 5 minutes with the aid of two 16-107 
beam infrared arrays. Time spent in the center of the arena was used as an index of anxious behavior. 108 
Total distance traveled was used as an indicator of locomotor activity. 109 
Elevated-Plus Maze(EPM) test was used to access anxious behavior. Briefly, animals were placed in 110 
the center of the EPM apparatus and entries as well as time spent in open and closed arm were 111 
measured for 7 min as previously described 21. Data were collected using a CCD camera by the use 112 
of NIH Image program (http://rsb.info.nih.gov/nih-image/) and were analyzed using customized 113 
software based on Matlab (version 7.2, Mathworks Co Ltd, CA) with image analysis tool box 114 
(Mathworks Co Ltd, CA). 115 
Y-Maze test was used to assess PFC-dependent memory based on spontaneous alternation task. 116 
Briefly, animals were placed in the center of the Y-maze apparatus (33cm x 7cm x 15cm) and allowed 117 
to freely move for 8 minutes. The number and order of arm entries was recorded. Spontaneous 118 
alternations were calculated as the ratio of number of triads (sequence of three consecutive arm 119 
entries) and total arm entries.  120 
Reversal Learning test was performed in swimming circular pool (1m diameter) filled with water (24ºC) 121 
made opaque with a white bio-safe dye. The cylinder contained a slightly submerged transparent 122 
escape platform and placed in a room with landmark (reference) objects. Learning trials (3 trials/day; 123 
60-s trial period) start by gently placing mice on the water surface close to the cylinder wall. After 124 
subjected to probe test, animals were tested (4 trials) for reversal learning task where the platform 125 
was moved to the opposite quadrant of swimming pool. Swim path of each animal was recorded by a 126 
CCD camera and analyzed using customized software based on Matlab (version 7.2, Mathworks Co 127 
Ltd, CA) with an image analysis tool box (Mathworks) 20,22.  128 
Contextual Fear Conditioning (CFC) test was conducted CFC sound- and light- proof chambers (Med 129 
Associates, St. Albans, VT). On day 1, mice were placed in the conditioning white chamber (Context 130 
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A) and received 3 pairings of light (20 sec) and a co-terminating electrical shock (2 sec, 0.5 mA). The 131 
chambers were cleaned with 10% ethanol between animal trials. On day 2, animals were placed in 132 
the same context (context A) in the absence of the light-shock stimuli. After it, the animals returned to 133 
their home cage. Two hours later, the animals were placed in a new context (context B) for 3 min. 134 
The context B trial was different from context A in several ways: i) the floor and walls of the 135 
chamber were covered by black plastic inserts; ii) the chamber was scented with vanilla; iii) the 136 
chamber ventilation fan was turned on; iv) the experimenter wore a different style and color of 137 
gloves, mask and lab coat; v) mice were kept in a different holding room before testing and 138 
transported in a different cage; vii) the lights of the experimental room were turned on. Mice 139 
behavior was recorded by CCD camera and freezing behavior was manually scored using Kinoscope 140 
software (http://sourceforge.net/projects/kinoscope/). 141 
 142 
Biochemical fractionation and immunoblotting 143 
Hippocampus and medial prefrontal cortex (PFC) tissue was macrodissected (on ice) and immediately 144 
stored at –80ºC. For detecting insoluble Tau, the sarkosyl-based fractionation protocol was used as 145 
previously described 20,23. After homogenization in Tris-HCl buffer (10mM Tris, 150mM NaCl including 146 
protease and phosphatases inhibitors), lysates were centrifuged at 100.000g. The pellet was re-147 
homogenized in salt/sucrose buffer (0.8M NaCl, 10mM Tris-HCl, 1 EGTA, pH=7.4, 10% sucrose 148 
solution including protease and phosphatases inhibitors. After addition of 10% Sarkosyl solution 149 
(Sigma, #L-5125), incubation (37ºC; 1h) and centrifugation (150.000g), the resulting pellet was 150 
analyzed as sarkosyl-insoluble fraction. As insoluble stress granules (SGs) cannot be detected in 151 
sarkosyl-insoluble fractions 18, we separate soluble and insoluble SGs using RIPA buffer (50 mM Tris, 152 
1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1mM EGTA, including protease and 153 
phosphatase inhibitors) as previously described 19. Homogenates were layered onto 0.32 M sucrose 154 
buffer (0.32 M sucrose, 10 mM Tris-HCl, 0.8 M NaCl, 1 mM EGTA) and were centrifuged (20000g, 10 155 
min, 4ºC). The supernatants were ultracentrifuge at 112.000g (60 min; 4ºC). The supernatant (soluble 156 
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fraction) was collected and stored at -20ºC. The remaining pellet was dissolved in 1% SDS/RIPA 157 
buffer and centrifuged at 112000g (60 min; 4ºC; 2 times) followed by 1% SDS/TBS buffer and 158 
ultracentrifugation (60 min; 20ºC). The final pellet was dissolved in 70% formic acid and centrifuged 159 
at 20000g (10 min; 20ºC). The supernatant was concentrated in speed vacuum and the resulting 160 
pellet dissolved in sample buffer and neutralized with 1.5M Tris-HCl providing the insoluble SG 161 
fraction.  162 
The above samples were electrophoresed using SDS-PAGE gels (17%-acrylamide gel for LC3II 163 
detection, 10%-acrylamide for the remaining proteins) and semi-dry transferred onto nitrocellulose 164 
membranes (Trans-Blot Turbo blotting system, BIORAD). Membranes were blocked with 5% nonfat 165 
dry milk in TBST-T buffer and then, incubated with the following antibodies: actin (1:2500; ABCAM, 166 
#ab8224), LC3 (1:1000; Novus Biologicals, #100-233), SQMTS1/p62 (1:1000;Novus Biologicals, 167 
#H00008878-M01), S6K total (1:750; Cell Signaling, #2708), p-S6K (1:750; Cell Signaling, #9205), 168 
p38 total (1:750; Cell Signaling, #9212) and p-p38 (1:750; Cell Signaling,#4511); eIF4E (1:500, Santa 169 
Cruz, #sc-9976), mTOR total (1:500; abcam #32028), p-Ser2448-mTOR (1:200; Cell Signaling, 170 
#5536), Tau5 (1:2000; ABCAM, #ab80579), JM (1:1000; kindly gift by Dr A. Takashima, Japan, 171 
recognizes human Tau), TLS/FUS (1:500; ABCAM, #84078), EWRS1 (1:1000; ABCAM, #133288), 172 
DDX5 (1:1000; ABCAM, #21696), TIA-1 (1:500; ABCAM, #40693), PABP (1:500, ABCAM #21060), 173 
tubulin (1:5000, SIGMA #9026), Ac-tubulin (1:1000, ABCAM #24610), Cortactin (1:250, ABCAM 174 
#81208), Ac-cortactin (1:10000, Millipore #09881) and HDAC6 (1:100, ABCAM #1440). After 175 
incubation with appropriate secondary antibody, antigens were revealed by ECL (Clarity, Bio-Rad), 176 
and signal quantification was achieved using a ChemiDoc instrument and and ImageLab software 177 
(Bio-Rad). All values were normalized and expressed as a percentage of control values. 178 
 179 
 180 
Immunofluorescence and stereological analysis 181 
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As previously described 20, deeply anesthetized animals were transcardially perfused with saline and 182 
PFA (4%). After post-fixation, brains were placed in 30% sucrose and sectioned using vibratome. 183 
Sections were exposed to antigen retrieval by citrate buffer, followed by 0.3% Triton X-100 before 184 
blocking with solution (5% BSA in TBS-Triton X-100 (0.25%) + 5% FBS) for 30min (RT).  Then, 185 
incubation with appropriate primary antibody: LC3 (1:100; Novus Biologicals), SQMTS1(p62) (1:500; 186 
Novus Biologicals), TIA-1 (1:200; ABCAM, #40693), PABP (1:100, mouseAb, SantaCruz #166381), 187 
PABP (1:200, rabbitAb, ABCAM #21060) and PHF1(1:100, kindly provided by Dr. Peter Davies), 188 
followed by incubation with the appropriate secondary antibodies and  DAPI staining (1:1000; 10 min). 189 
For LC3 and p62, stained cells were counted and densities were quantified and normalized for number 190 
of cells using the Olympus BX 51 stereological microscope and the Visiopharma integrator system 191 
software. Neuronal densities of hippocampal and PFC areas (DG, CA1 and PrL) were stereologically 192 
estimated by counting neurons in cresyl-violet stained serial coronal  brain sections, using 193 
Neurolucida software (MBF Bioscience, Williston, VT) as previously described 24,25. 194 
 195 
Human AD brain tissue 196 
Temporal cortex tissue from human brain was used for the immunohistochemical studies. Human 197 
tissue was sectioned at 20um on a cryostat and stained as free floating sections. To quench 198 
autofluorescence, sections were photobleached under a 1500 lumen white LED bulb for a minimum 199 
of 72 hours at 4°C while suspended in PBS26. Sections were then washed in PBS followed by TBS 200 
with 0.25% Triton-X incubation. Samples were then incubated in 1%w/v sodium borohydride (NaBH4; 201 
Sigma-Aldrich Cat#452882-25G) in PBS for 45 minutes to quench aldehyde autofluorescence which 202 
results from the over-fixation of tissue. Then citrate incubation was preformed, followed by solution 203 
(Vector Cat#H-3300) at 95°C, blocking with donkey serum in PBS-T; primary antibody incubation with 204 
PABP (1:150, ABCAM #21060), DDX6 (1:150, Bethyl Laboratories #A300-460A) and p-Tau-CP13 205 
(1:150, kindly provided by Dr. Peter Davies), was followed by incubation with the appropriate 206 
secondary. All imaging was done using a Zeiss LSM 700 confocal microscope. 207 
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 208 
P301L-Tau-SHSY5Y cells, treatments and analysis 209 
These studies used SH-SY5Y cells stably transfected with P301LhTau-EGFP (2N4R) (kind gift from 210 
Professor Juergen Gotz, University of Queensland, Australia). Cells were cultured in DMEM 211 
supplemented with 10% FBS 1% G-max and 1% antibiotic (37ºC and 5%CO2; all reagents obtained 212 
by Invitrogen); for selection purposes, 3ug/mL Blasticidin S hydrochloride (Sigma, #15205) was added 213 
in the medium. For all experiments, cells were placed on gelatin-coated plates and differentiated for 214 
6-7 days with differentiation medium [DMEM, 1% FBS, 1% antibiotics, 1% glutamax, 10-5M all-trans 215 
retinoic acid (Sigma)]. Each experiment has 3-4 biological replicates per condition, and experiments 216 
were repeated at least 3 times. Dexamethasone (DEX; Fortecortin®, Merck, Darmstadt, Germany) 217 
was used at a final concentration of 10-6M for 48h, as previously described9. For mTOR inhibition, 218 
Temsirolimus (CCI-779, LC Laboratories; 100uM; 48 hrs) was used; CCI-779 exhibits no toxicity in 219 
this concentration 27,28. Cell viability was assessed by MTS assay (CellTiter 96®, Promega, WI, USA) 220 
based on manufacturer instructions by the use of ELISA reader (BioRad); triplicates of each condition 221 
were used and experiment were repeated three times. For puromycin and cycloheximide treatment, 222 
cells were incubated with 5ug/ml of puromycin (Sigma #P8833) or 10ug/mL with cycloheximide 223 
(Millipore, #CAS-66-81-9) 6h before the end of the 48h DEX incubation period. For Bafilomycine 224 
treatment, cells were incubated with 10nM Bafilomycine A1(Bafilomycin A1 Santa Cruz #CAS-88899-225 
55-2) for 4hrs for analysis of autophagy flux. For WB analysis, cell homogenates were prepared in 226 
RIPA buffer (50mM Tris HCl, 2mM EDTA, 250mM NaCl, 10% glycerol, proteinase and phosphatase), 227 
After sonication and centrifugation (15min; 14.000rpm; 4ºC), supernatant samples were analyzed by 228 
WB as described above. Total and sarkosyl-resistant Tau aggregates of cell homogenates were 229 
detected after sample microfiltration. Briefly, 60 ug of samples were diluted in 200 ul of PBS with or 230 
without 1% (wt/vol) Sarkosyl and boiled for 5 min. Samples were filtered through a cellulose acetate 231 
membrane (0.2 µm, Whatman), pre-equilibrated in PBS, using a Bio-Dot SF microfiltration apparatus 232 
(Bio-Rad). The membrane was washed twice with PBS before being probed with Tau-5 antibody 233 
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(1:2500, Abcam) as described above. For IF analysis, cells were cultured in gelatin-coated glass 234 
coverslips and fixed in 4%PFA. After permeabilization with 0.1% TritonX-100/PBS, cells were 235 
incubated overnight with primary antibodies: LC3(1:200; Novus Biologicals, #100-233), 236 
SQMTS1(p62) (1:200; Novus Biologicals, #H00008878-M01), Tau-5 (1:1000; ABCAM, #ab80579), 237 
TLS/FUS (1:300; ABCAM, #84078), G3BP (1:500; ProteinTech, # 13057-2-AP), TIA-1 (1:300; 238 
ABCAM, #40693), HDAC6 (1:200; ABCAM, #ab1440). After appropriate fluorescence-conjugated 239 
secondary antibodies (RT, 30 min) and DAPI staining, cells were analyzed by laser confocal 240 
microscopy (Zeiss LSM 510, Carl Zeiss Microimaging, Goettingen, Germany).  241 
 242 
Statistical Analysis 243 
Numerical data is expressed as group mean±SEM. All data were evaluated by Student’s t-test or one-244 
way ANOVA (followed by poshoc Sidak test) when appropriate, using GraphPad 6.0; differences were 245 
considered to be significant if p< 0.05. 246 
 247 
Results  248 
Chronic stress triggers accumulation of neurotoxic Tau aggregates in hippocampus and 249 
prefrontal cortex of P301L-Tau Tg mice. 250 
The hippocampus and the prefrontal cortex (PFC) are some of the brain areas most affected in AD, 251 
exhibiting a characteristic accumulation of pathological, aggregated Tau (e.g. hyperphosphorylated, 252 
truncated and misfolded); the accumulation of pathological Tau is closely correlated with cognitive 253 
impairment 29,30. Previous studies have shown that stress and GC trigger aberrant 254 
hyperphosphorylation, misfolding and missorting of Tau 7,9,31,32. In the current study, we sought to 255 
clarify the impact of chronic stress on Tau aggregation mechanism(s) and resulting behavioral deficits. 256 
These studies use the P301L-Tau transgenic mice expressing 4R0N human Tau carrying the 257 
aggregation-prone P301L-Tau mutation20; these mice were then subjected to chronic unpredictable 258 
stress. Stressed P301L-Tau animals exhibited a clear decrease in body-weight in comparison to 259 
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control (non-stressed) animals (Fig. 1a). They also showed elevated levels of the stress hormone, 260 
corticosterone (Fig. 1a), providing confirmation of the stress protocol efficacy. To access 261 
hippocampus-dependent cognitive performance, Contextual Fear Conditioning test (CFC) was used. 262 
While both groups showed similar freezing levels in pre-training session of context A, stressed animals 263 
exhibited lower levels of freezing at the next day (Context A) compared to control animals indicating 264 
deficits of associated memory (Fig. 1b). Of note, the stress-driven difference disappeared when both 265 
groups where tested in another, non-associated with adverse stimulus, context (context B) (Fig. 1b). 266 
Furthermore, animals behavioral flexibility and working memory function were tested using the 267 
reversal learning and Y-maze test, respectively. During the reversal learning test, stressed animals 268 
exhibited an increase in the time to reach the escaping platform placed at the opposite quadrant in 269 
comparison to control animals suggesting cognitive deficits (Fig. 1c). In the Y-maze, stressed mice 270 
presented a decrease in the percentage of spontaneous alternations among different arms of the Y-271 
maze apparatus (Fig. 1d), pointing towards a stress-driven impairment in working memory. As non-272 
cognitive neuropsychiatric symptoms, such as anxiety, are frequently observed in AD 33, we also 273 
evaluated anxious behavior using open field (OF) and elevated-plus maze (EPM). We found that 274 
chronic stress decreased the time that animals spent in the center of the OF arena (Fig. 1e) and 275 
reduced both time and entries in the open arms of EPM apparatus (Fig. 1f). Notably, stress did not 276 
cause any change in locomotion as assessed by total distance travelled in the OF apparatus (Fig. 277 
1e). The above stress-driven behavioral deficits in P301L-Tau Tg animals were accompanied by 278 
increased levels of Sarkosyl-insoluble Tau, in both hippocampus and PFC, of stressed animals as 279 
measured by Western blot analysis (Fig. 1g). These Tau aggregates are biochemically similar to those 280 
found in the neurofibrillary tangles that characterize AD and other Tauopathies 30. Furthermore, 281 
P301L-Tau aggregates are shown to exhibit a major trigger of neurotoxicity in Tau pathology 20, which 282 
is in line with the reduction of cell density that stressed P301L-Tau animals exhibited in hippocampus 283 
(CA1 and DG) and PFC (prelimbic cortex; PrL) when compared to control P301L-Tau animals (Fig. 284 
1h).  285 
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 286 
Stress-driven inhibition of autophagy through mTOR activation 287 
A growing body of research has connected autophagy to neurodegenerative pathology while 288 
autophagic clearance has been suggested to exhibit selectivity for the degradation of Tau aggregates 289 
11. Accordingly, we have monitored autophagy focusing on LC3 and p62, the most widely used 290 
indicators of autophagic flux (Fig. 2a). Molecular analysis of hippocampus and PFC of P301L-Tau 291 
animals showed that chronic stress reduced the levels of LC3 and increased levels of p62 (Fig. 2b) in 292 
hippocampus and PFC; this was further confirmed by parallel shifts in the IF intensity of LC3 and p62 293 
(Fig. 2c-e). As many studies describe an essential role for mTOR in protein homeostasis through its 294 
involvement in the initiation of autophagic process 34, we assessed mTOR activity by analyzing mTOR 295 
and some of its downstream targets (Fig. 2f).  We found that chronic stress increased the levels of 296 
phosphorylated mTOR and the stress-activated protein kinase, p38; the later is suggested to be 297 
involved in both Tau pathology and mTOR activation35–37. Furthermore, the phosphorylated levels of 298 
downsteam mTOR target, S6K was also elevated by stress while the protein levels of the downstream 299 
target, eIF4E were decreased by chronic stress (Fig. 2f). Altogether, the above findings suggest that 300 
exposure to chronic stress may inhibit autophagy, probably at the level of mTOR-mediated induction 301 
of autophagy (Fig. 2a).   302 
 303 
Glucocorticoid treatment mimic the stress-driven effect on aggregation-enhancing 304 
neurodegenerative cascades in vitro. 305 
Despite the fact that the detrimental effects of chronic stress on neuronal structure and function are 306 
largely attributed to GC 38, and previous work highlights the role of glucocorticoid receptor (GR) in Tau 307 
malfunction and pathology 7,9, other studies exclude GC and GR signaling from the effect of stress on 308 
Tau 39. Thus, we next tested the impact of prolonged treatment with high GC levels using the synthetic 309 
glucocorticoid dexamethasone on a neuronal cell line expressing P301L-Tau tagged with GFP. We 310 
found that GC treatment (10-6M, 48hr) caused increase of GFP-labelled P301L-Tau protein as well as 311 
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total Tau levels (Fig. 3b-c) in parallel to decreased cell viability (Fig. 3a). In addition, WB analysis 312 
revealed that GC impacted both on wild-type (human)Tau and exogenously-expressed (P301L-Tau) 313 
human Tau protein as well as insoluble levels of Tau (Fig. 3c-d). Using both IF and WB analysis, we 314 
found that autophagic markers such as LC3, p62 are also affected by GC treatment. In line with our 315 
in vivo findings in P301L-Tau mice, GC treatment of P301L-Tau cells led to an increase in p62 levels 316 
accompanied by a reduction in LC3II measured by WB analysis (Fig. 3e). Accordingly, we also 317 
observed a decrease in LC3+ puncta after GC exposure (Fig. 3f). Furthermore, in another experiment 318 
moniroting autophagic flux by bafilomycin A1, a known inhibitor of the late phase of autophagy, GC 319 
led to accumulation of p62 in parallel to a decrease of LC3II levels compatible with an inhibition of 320 
autophagy (Supplementay Fig. S1). Altogether, the above results indicate that GC induced a blockage 321 
of autophagic clearance and accumulation and aggregation of Tau. 322 
 323 
Chronic stress  and glucocorticoids trigger accumulation of Stress granule-related proteins  324 
The cellular stress response under pathological conditions includes the translational stress response, 325 
which results in the dysregulation of RBPs and consequent SG formation. These SGs have also 326 
recently been shown to stimulate the accumulation of aggregated Tau 16,18. As inhibition of autophagic-327 
lysosome pathway was recently shown to impair the degradation and dynamics of SGs 15, we next 328 
monitored different SG-related proteins as well as their insoluble accumulation in P301L-Tau animals 329 
under control and stressful conditions.  330 
Our analysis showed the presence of different RBPs and SGs markers in soluble and insoluble 331 
fractions of homogenates of P301L-Tau mice under control (non-stressed) conditions (Fig. 4), which 332 
is in line with previous studies that show the association of many SG-related proteins with pathological 333 
Tau 18,19. In addition, we observed that chronic stress significantly elevated cytoplasmic localization 334 
of TIA-1, and also increased the soluble levels of RBPs proteins TIA-1, DDX5, EWRS1 and TLS/FUS 335 
(Fig. 4a); similar increases of insoluble levels of TLS/FUS, DDX5 and PABP were observed with 336 
chronic stress (Fig. 4b). Notably, TIA-1 was not detected in the insoluble fraction in contrast with 337 
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previous work that did not utilize a stress model 18,40. Confirming the above results, 338 
immunofluorescence staining demonstrated that chronic stress increased total and cytoplasmic TIA-339 
1 staining in hippocampus together with a striking increase in cytoplasmic co-localization with Tau 340 
phosphorylated at amino acids 396 & 404, detected with the PHF1 antibody (Fig. 4c). We also 341 
observed an increase in PABP staining in hippocampus after stress, that co-localizes with PHF-1 p-342 
Tau (Fig. 4d) and TIA-1 (Fig. 4e). RNA binding proteins, such as DDX6 and PABP, diffuse around 343 
PHF-1 p-Tau inclusions in human AD brain (Fig 4f), although in the human brain the RBPs appear 344 
adjacent to the inclusion, which reflects increasing exclusion as the tau pathology consolidates; similar 345 
findings are observed in late stage mouse models of tauopathy 19. Thus, these findings suggest that 346 
chronic stress triggers the accumulation of different SG-related proteins which points towards a 347 
potential role for RBPs dysregulation in stress-driven Tau pathology.  348 
GC exposure in a cell line of SY5Y cells stably expressing P301L-Tau also resulted in increased 349 
cytoplasmic levels and inclusions of different SG-related proteins such as TIA-1, TLS/FUS, DDX5 and 350 
G3BP (Fig. 5a). IF staining confirmed the GC-induced increased labeling of SG-related proteins TIA-351 
1 and G3BP with increased TIA-1 reactivity and cytoplasmic translocation under GC exposure (Fig. 352 
5b-c). For further monitoring the role of SG-related proteins in GC-driven Tau accumulation, we co-353 
treated P301L-Tau cells with GC and either cycloheximide (CHX) or puromycin (PUR); two 354 
compounds that are protein synthesis inhibitors, but exhibit opposite effects on SG, promoting (PUR) 355 
or inhibiting (CHX) SGs assembly, respectively 19. We found that GC and PUR co-treatment 356 
exacerbated the GC-induced increase of Tau (Fig. 5d), followed by increased levels of TIA-1 357 
(Supplementary Fig. S2). In contrast, GC and CHX co-treatment partially attenuated GC-driven 358 
accumulation of Tau (Fig. 5e) suggesting a critical role for RBPs accumulation and the related SGs in 359 
the cellular mechanisms of GC-driven Tau accumulation.   360 
 361 
Chronic stress and glucocorticoids impact on HDAC6 and its cytoplasmic downstream 362 
targets 363 
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Importantly, SGs as well as different parts of autophagic process (e.g. autophagosome maturation) 364 
rely on microtubule-based networks and cytoskeletal machinery. Histone deacetylase 6 (HDAC6) 365 
regulates SGs and autophagy through its influence on different cytoskeletal molecules (e.g. tubulin, 366 
cortactin), and corresponding regulation of microtubule-dependent motility 41,42. Because HDAC6 is 367 
required for the consolidation of cellular complexes related to SGs and autophagy 41,42, we proceeded 368 
to analyze the impact of GC on HDAC6 and its cytoskeletal targets. WB and IF analyses revealed 369 
that HDAC6 levels were increased by chronic stress and GC in P301L-Tau mice and cells (Fig. 6a, 370 
6c, 6e) which was accompanied by a decrease in acetylation levels of the cytoskeletal targets of 371 
HDAC6, tubulin and cortactin (Fig. 6b, 6d). Matching with the above stress-driven deficits in 372 
autophagic and SG-related RBPs, these data suggest a potential cytoplasmic role of HDAC6 in the 373 
stress/GC-driven cellular cascades related to imbalanced Tau proteostasis.  374 
 375 
Pharmacological stimulation of autophagy attenuates GC-driven neurotoxic cascades. 376 
Mounting evidence supports mTOR as an important regulator of protein homeostasis 13 while the 377 
above in vivo data suggest that the inhibitory effect of stress on autophagic process is mTOR-related. 378 
Thus, we next clarified whether pharmacological inhibition of mTOR could protect against GC-driven 379 
Tau-related neurotoxicity. For that purpose, we used a rapamycin analog, Temsirolimus (CCI-779) 380 
shown to be safe and recently approved by USA and European Drug authorities 43. Co-treatment of 381 
CCI-779 with GC attenuated the reduced cell viability caused by GC (Fig. 7a) providing 382 
neuroprotection. Furthermore, we found that GC+CCI co-treatment reverted the changes that GC 383 
evoked on different autophagy-related molecules (Fig. 7b). Specifically, GC+CCI-779 co-treatment 384 
increased LC3II with similar reverse changes in p62 protein levels (Fig. 7b). Additional confirmation 385 
was also obtained by LC3 staining, where LC3+ puncta in GC+CCI treated cells was increased to 386 
control levels (Fig. 7c), suggesting that CCI-779 blocked the GC-evoked impact of autophagic 387 
process. Moreover, CCI-779 treatment attenuated the GC-driven elevation of both exogenous (EGF-388 
P301L-Tau) and endogenous (wildtype) Tau, as shown by both WB (Fig. 7e) and IF approaches (Fig. 389 
 16 
7d), while it also reduced the levels of insoluble Tau aggregates (Fig. 7f); note that  CCI alone had no 390 
impact on Tau levels (Supplementary Fig 3). Interestingly, CCI-779 blocked the GC-evoked elevation 391 
of different RBPs including TIA-1, G3BP, TLS/FUS and DDX5 as assessed by WB (Fig. 8a) and IF 392 
analysis (Fig. 8b-c). Note that CCI-779 treatment blocked the GC-triggered cytoplasmic translocation 393 
and accumulation (in puncta) of the SGs core-nucleating protein TIA-1 preserving its localization to 394 
nucleus (Fig. 8b). These findings suggest that CCI-779-evoked mTOR inhibition can attenuate the 395 
GC-evoked neurodegenerative cascades underlying Tau neurotoxicity. 396 
 397 
Discussion  398 
Understanding the molecular mechanisms that promote Tau misfolding and aggregation are of critical 399 
importance because of the key role played by Tau in mediating toxicity and neurodegeneration in AD 400 
30,44. Although multiple preclinical and clinical trials have focused on Tau anti-aggregation strategies 401 
with different compounds 45,46, there remains a pressing need for new strategies to prevent disease 402 
progression in AD.  403 
The putative role of prolonged stress and excessive GC exposure in increasing brain vulnerability to 404 
disease pathology could have important implications for treatment of AD. Clinical studies reported a 405 
negative correlation between high cortisol levels and memory scores in AD subjects 5 and other 406 
implicate the activity of the hypothalamus-pituitary-adrenal (HPA) axis in the disease process4. 407 
Chronic stress is also correlated with earlier age of onset in familial AD 6, which further highlights a 408 
potential role of chronic stress and GC in the pathogenesis and/or progression of AD. Direct support 409 
of the neurodegenerative potential of chronic stress is provided by multiple experimental studies, 410 
including ours, that show stress and GC trigger different parameters of Tau pathology such as 411 
aberrant hyperphosphorylation, somatodendritic accumulation 1,7 and synaptic missorting31,32. In 412 
addition, we have recently demonstrated that chronic stress also induces truncation and misfolding of 413 
Tau leading to the formation of neurotoxic Tau aggregates8.  414 
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In the current study, we demonstrate that activation of the mTOR pathway is required for the effect of 415 
chronic stress and GC on Tau pathology, as the mTOR inhibitor (CCI-779) blocked the GC impact on 416 
Tau proteostasis (Fig. 8d). One of the main actions of mTOR inhibition is activation of autophagy. 417 
These results expand previous in vitro and in vivo observations showing that stress/GC reduced Tau 418 
turnover 9 and deregulates molecular chaperones responsible for Tau proteostasis8. Autophagy is 419 
thought to play a more important role than the proteosome in the catabolism of pathological Tau 47,48 420 
because the engulfing mechanism used by the autolysosomal system is more capable than the 421 
proteasome at degrading large macromolecular structures10. The potential role of autophagy is 422 
strongly supported by studies highlighting a specific relationship between autophagy deficits and Tau 423 
pathology in brains of AD patients and animals models of Tauopathies 49,50.  424 
Autophagy is a highly-regulated process that is initiated by changes in phosphorylation states of 425 
individual components such as the Unc51-like-kinase (ULK) complex, which is mainly regulated by 426 
mTOR. Interestingly, mTOR signaling is altered in AD51,52, with the levels of mTOR and its 427 
downstream targets, including p70S6K, being increased in AD human brains13. Accordingly, our 428 
current findings demonstrate that chronic stress and GC increase markers of mTOR activation and 429 
authophagic inhibition. We observed increased levels of phosphorylated mTOR and S6K, indicators 430 
of active mTOR signaling, as well as a reduced LC3II/LC3I ratio and an accumulation of p62. These 431 
findings suggest that chronic stress activates the mTOR pathway, which inhibits autophagy. The 432 
putative role of mTOR is supported by prior studies showing that chronic stress triggers mTOR 433 
activation in the hippocampus53, and that mTOR activation is associated with increased total Tau 434 
levels in AD brains54. We further demonstrate that the use of the mTOR inhibitor, CCI-779, blocks the 435 
GC-driven Tau-related neurotoxicity and induction of aggregation-related cascades which is 436 
consistent with prior studies that show a decrease of mTOR signaling reverts Tau pathology 27,55. 437 
These cumulative results point to a critical role for mTOR-dependent autophagy in the cellular 438 
mechanisms through which GC may trigger accumulation of Tau and its aggregates. 439 
 18 
Recent studies from AD and FTDP human brains as well Tau Tg mice suggest that RBPs 440 
dysregulation and SGs represent a novel pathway that may contribute the development and 441 
progression of Tau pathology16,19. SGs are cytoplasmic complexes composed of phase separated 442 
complexes containing mRNAs and RNA-binding proteins (RBPs), which form to sequester non-443 
essential transcripts in response to cellular stress. SGs are thought to constitute a protective 444 
mechanism against cellular stress by directing ribosomal system to translate mRNA transcripts coding 445 
for cytoprotective proteins 16. The process of liquid-liquid phase separation and reversible aggregation 446 
that underlie SG formation is meant to be a transient event, but with prolonged SG induction is 447 
hypothesized to become pathological and neurotoxic 18,19. SGs have been suggested to accelerate 448 
Tau aggregation while, in a vicious cycle, Tau stimulates SG19. Factors known to stimulate Tau 449 
aggregation, including hyperphosphorylation and aggregation-prone mutations, also enhance the 450 
interactions between SGs and Tau 19.  451 
The current study suggests a novel role for RBPs in the stress/GC-driven neuronal pathology. We 452 
demonstrate for the first time that chronic stress increase the cytosplasmic levels of different RBPs 453 
and SG-associated markers (e.g. TIA-1, PABP, G3BP, FUS, DDX5) leading to its insoluble 454 
inclusion/accumulation. While SG biology involves the action of multiple different proteins leading to 455 
RBPs accumulation which is necessary for SGs56–58, recent evidence demonstrates that TIA-1 pocess 456 
a primary role in the SG-related mechanism of Tau aggregation. Specifically, TIA-1 is transported 457 
from nucleus (where is predominantly found) to cytospasm where it interacts directly with Tau to 458 
stimulate its aggregation and insoluble accumulation/inclusion of other RBPs such as PABP and 459 
EWSR1 17,19,59. This is of particular importance as our current findings show that, under stressful 460 
conditions, TIA-1 is traslocated from nucleus to cytosplam accompanied by insoluble accumulation of 461 
different SGs-associated proteins and Tau aggregates; future work should further study whether and 462 
how this RBP dysregulation and insolubilization correlates to altered SG formation. Furthermore, we 463 
have recently shown that Tau missorting and dendritic accumulation are also part of chronic stress/GC 464 
hippocampal pathology 31,32 while missorting of Tau are hypothesized to facilitate formation of SGs as 465 
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part of the translational stress response 19. While the temporal profile and precise mechanisms 466 
underlying the stress/GC-evoked dysregulation of RBPs and SG-associated cascade remain to be 467 
elucidated, the working model suggested in this study (see Fig. 8d) opens a novel window of research 468 
and therapeutic exploration focusing on biology of RNA-protein interplay in stress-related pathologies. 469 
The interface between autophagy and RBPs dysregulation and insolubilization that we highlight in this 470 
manuscript is supported by studies suggesting that inhibition of autophagy may impact in the 471 
dynamics and removal of SGs 15,60. Whether this occurs in the brain and in particular disease models, 472 
was not previously known. The cytoskeletal machinery is known to facilitate the aggregation of RBPs 473 
to form SGs, contribute to maturation of autophagic vesicles and autophagosome/lysosome fusion 474 
61,62. One of the molecules involved in these processes is histone deacetylase 6 (HDAC6), which, 475 
through the deacetylation of tubulin, reduces microtubule-dependent motility and thereby promotes 476 
the consolidation of cellular complexes such as SGs and autophagosomes 41,42,63. Mounting evidence 477 
implicates HDAC6 in the formation of SGs in AD brain as HDAC6 seems to co-localize and interact 478 
with SG proteins under cellular stress; interestingly, HDAC6 is a SGs component interacting with 479 
G3BP 64,65. Additionally, pharmacological inhibition or genetic ablation of HDAC6 abolished SG 480 
formation 66, while the expression of HDAC6 significantly increases in the hippocampus and other 481 
brain regions of AD patients as well as in animal models of the disease 67,68. Our findings show that 482 
stress and GC increased HDAC6 levels, resulting in reduced acetylated levels of HDAC6’s 483 
cytoskeletal targets e.g. tubulin. Reduced acetylation of tubulin is associated with microtubule 484 
instability, which is also suggested to cause enlargement of SGs 69. Interestingly, recent reports in 485 
mice show that HDAC6 inhibition increases resilience to stress 70,71. While these findings point to 486 
HDAC6 as a potential regulator in the stress-driven Tau pathology (see Fig. 8d), future studies should 487 
clarify its specific role in different cellular pathways evoked by chronic stress and GC.  488 
In conclusion, the current study adds to our limited knowledge about how chronic stress increases 489 
brain vulnerability to disease aiming to illuminate novel fundamental molecular mechanisms through 490 
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Fig. 1. Chronic stress evokes accumulation of neurotoxic Tau aggregates causing cognitive 705 
and emotional deficits in P301L-Tau Tg mice. a P301L-Tg mice exhibited reduced body weight 706 
(p=0.005) and increased corticosterone (p<0.001) levels after chronic environmental stress. b In 707 
contrast to pre-training session (p=0.171), stressed animals exhibited a significant decrease in 708 
percentage of freezing time in test section (context A) of CFC in comparison to control animals 709 
indicating hippocampus-dependent associative memory impairment (p<0.001); note that both animal 710 
groups exhibit similar freezing levels in context B which is not non-associated with the adverse stimuli 711 
animals received in context A (p=0.640). c Chronic stress increased the time that animals swum to 712 
reach the new (opposite) place of the escaping platform indicating PFC-dependent deficits of 713 
behavioral flexibility (p=0.046). d Stress also reduced percentage of spontaneous alternations in the 714 
arms of a Y-maze as compared with control animals pointing to deficits of working memory (p=0.007). 715 
e-f Whereas no different in total distance travelled by animals in OF apparatus (p=0.988), stressed 716 
animals exhibited a decrease in time spent in the center of the OF arena (p=0.003) (e) followed by 717 
reduced time (p=0.004) and entries (p=0.001) that animals spend in the open arms of EPM apparatus 718 
(f); these behavioral parameters suggest increased levels of anxiety in stressed animals compared 719 
with controls. g-h Chronic Stress elevated the levels of Tau in sarkosyl-insoluble in both hippocampus 720 
and PFC of P301LTau mice (Hipp: p=0.028; PFC: p<0.001) (g); an effect that was accompanied by 721 
decreased cell density in PFC (prelimbic cortex; PrL: p<0.001) and hippocampus (DG: p<0.001; CA1: 722 
p<0.001) (h). All numeric data represent mean ± SEM, *P<0.05; **P<0.01; ***P<0.001. 723 
 724 
Fig. 2. Prolonged exposure to environmental stress inhibits autophagy in a mTOR-dependent 725 
manner. a Schematic representation of autophagy highlighting the role of mTOR, LC3 and p62 in this 726 
cellular process. b-e Stressed animals exhibited reduced LC3 (PFC: p=0.003; HIPP: p=0.026) and 727 
increased p62 (PFC: p=0.029; HIPP: p=0.004) protein levels as assessed by WB analysis (b); these 728 
findings were confirmed by corresponding changes in LC3+ (p=0.044) and p62+ (p=0.044) 729 
fluorescence intensity/cell number (c-d) an decrease in their co-localization (e), indicating a stress-730 
driven inhibition of autophagic process. f In line with the above findings, the levels of phospho S6K 731 
(p=0.014), p38 (p=0.030) and mTOR (p<0.001) proteins were increased by stress, with decrease 732 
levels of eIF4E (p=0.024), which are indicative of mTOR activation. All numeric data represent mean 733 
± SEM, *P<0.05; **P<0.01; ***P<0.001. 734 
 735 
Fig. 3. Exposure to glucocorticoids causes Tau accumulation and autophagy inhibition in 736 
vitro. a GC treatment (10-6M; 48hr) of EGF-P301L-hTau SHSY cells decreased cell viability 737 
(p=0.004). b-d Glucocorticoid (GC) treatment triggered cytoplasmic accumulation of exogenously 738 
expressed mutated human Tau (EGF-P301L-Tau) and endogenous human Tau (WT-Tau) as 739 
Silva et al 
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assessed by IF (f) (p=0.044) (b) and WB analysis (c)  (WT-Tau: p<0.001; EGF-P301L-Tau: p=0.001), 740 
and lead to increased levels of insoluble Tau aggregates (p=0.042) (d). e-f GC decreased LC3II 741 
(p=0.013) protein levels with parallel increase of p62 (p=0.039) (e); immunofluorescence analysis 742 
confirmed the GC-induced reduction in LC3 (p=0.004) puncta (f). All numeric data represent mean ± 743 
SEM, *P<0.05; **P<0.01; ***P<0.001. 744 
 745 
Fig. 4. Chronic stress evokes dysregulation of RBPs and their insoluble accumulation in 746 
P301L-tau Tg mice. a-b Chronic stress triggered an increase in the protein levels of several RBPs 747 
and SG markers in soluble fraction [TIA-1 (p=0.013), TLS/FUS (p=0.017), DDX5 (p<0.001) and 748 
EWRS1 (p=0.005)] (a), as well in insoluble fraction of P301L-Tau mice [DDX5 (p=0.02) and PABP 749 
(p=0.011)] (b). c-d Chronic stress causes the cytoplasmic accumulation of the SG marker TIA-1 in 750 
hippocampus (c) and the accumulation of PABP, a SG marker (d), increasing their co-localization with 751 
p-Tau (PHF1). e Moreover, chronic stress leads to an increase co-localization of TIA-1 and PABP in 752 
perinuclear region of hippocampal neurons, indicating the presence of TIA-1 positive stress granules. 753 
f Immunofluroresecent analysis of PABP and DDX with p-Tau in human AD brain. All numeric data 754 
are represented as mean ± SEM, *p<0.05; **p<0.01; ***p<0.001. 755 
 756 
Fig. 5. Dysruption and insoluble accumulation of RBPs in GC-driven Tau accumulation. 757 
Treatment of EGF-P301L-hTau SHSY cells with GC (10-6M; 48hr) elevated the cytoplasmic levels of 758 
the RBPs, TIA-1 (p=0.043), TLS/FUS (p=0.034), G3BP (p=0.004) and DDX5 (p=0.038) as assessed 759 
by WB analysis. b-c IF staining of TIA-1 (b) and G3BP (c) demonstrate that GC triggered their 760 
accumulation and cytoplasmic appearance in EGF-P301L-hTau SHSY cells. d Co-treatment of GC 761 
and puromycin (PUR), a well-known SG inducer, aggravate levels of EGF-P301L-Tau (p=0.013) and 762 
WT-Tau (p=0.023) when compared to GC treatment. e While co-treament of GC and CHX (the later 763 
inhibits SG formation) blocked the GC-driven Tau increase (p<0.001). All numeric data are 764 
represented as mean ± SEM, *p<0.05; **p<0.01; ***p<0.001. 765 
 766 
Fig. 6. Stress and glucocorticoids induce HDAC6 reducing the acetylation levels of its 767 
cytoplasmic targets. a-b Chronic stress elevated HDAC6 levels (p=0.004) (a) and reduced 768 
acetylation of tubulin (p=0.016) and cortactin (p=0.048), two cytoskeletal targets of HDAC6, in P301L-769 
Tau mice (b).  c-e GC treatment increased HDAC6 (p<0.001) as analyzed by WB (c) and elevated 770 
HDAC6 staining in P301LTau cells (p=0.041) (e), in parallel with decreased levels of acetylated forms 771 
of tubulin (p=0.004) and cortactin (p<0.001), two cytoskeletal targets of HDAC6 (d). All numeric data 772 
are represented as mean ± SEM, *p<0.05; **p<0.01; ***p<0.001. 773 
 774 
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Fig. 7. mTOR-driven pharmacological stimulation of autophagy blocked GC-triggered Tau 775 
accumulation. a-b Combined treatment of GC with CCI-779 (Temsirolimus), a rapamycin analog, 776 
attenuated the GC-driven decrease of cell viability (p=0.002) in EGF-P301LTau SHSY5Y cells (a) and 777 
reversed the GC effect on autophagy markers increasing protein levels of LC3II (p<0.001) with parallel 778 
decrease of p62 levels (p=0.001) (b). c IF staining of LC3 confirmed the CCI-779-evoked blockage of 779 
GC-driven reduction of LC3II puncta (p=0.0012). d-f CCI-779 treatment reduced the GC-driven 780 
elevated IF levels of GFP-P301LTau (p=0.002) (d); WB analysis revealed that CCI-779 attenuated 781 
the GC-driven accumulation of both EGF-P301L-Tau (p<0.005) and WT-Tau (p<0.001) levels (e), also 782 
leading to decrease in insoluble Tau levels (f). All numeric data are represented mean ± SEM, 783 
*p<0.05; **p<0.01; ***p<0.0001. 784 
 785 
Fig. 8. The CCI-779 inhibitor of mTOR attenuated GC-induced dysregulation of RBPs.  786 
a-c GC-driven increase of different RBPs [TLS/FUS G3BPand DDX5] was attenuated by co-treatment 787 
with CCI-779 (p=0.022; p=0.007; p=0.045, respectively) (a); IF staining of TIA-1 (b) and G3BP (c) 788 
confirmed the blockage of GC-driven induction of RBPs by CCI-779. c Working/hypothetical model 789 
integrating autophagy inhibition and dysregulation of RBPs in the cellualr mechanisms through which 790 
chronic stress and/or high levels of stress hormones, glucocorticoids (GC), precipitate Tau pathology. 791 
Chronic exposure to environmental stress and/or prolonged signaling of GC receptors (GR) evoke the 792 
activation of mTOR signaling and the induction of Histone deacetylase 6 (HADC6) and subsequently, 793 
reduce acetylation of proteins related to cytoskeletal instability. These cellular events lead to inhibition 794 
of autophagic process that, together with the dysregulation and insolubilization of RBPs and the 795 
potential formation of SGs, may contribute to the accumulation of Tau and its neurotoxic aggregates 796 
causing cell death and cognitive deficits. 797 
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